Last reviewed · How we verify
Varithena®
Varithena is a microfoam formulation of polidocanol that destroys varicose veins by causing endothelial damage and subsequent vein closure.
Varithena is a microfoam formulation of polidocanol that destroys varicose veins by causing endothelial damage and subsequent vein closure. Used for Varicose veins of the great saphenous vein, accessory saphenous vein, and visible varicosities.
At a glance
| Generic name | Varithena® |
|---|---|
| Also known as | Polidocanol Solution, 180 mg/18 mL (10 mg/mL) |
| Sponsor | Boston Scientific Corporation |
| Drug class | Sclerosing agent |
| Target | Vein endothelium (non-receptor mediated tissue damage) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular / Vascular |
| Phase | FDA-approved |
Mechanism of action
Varithena delivers polidocanol, a sclerosing agent, as a stable microfoam that displaces blood within the vein and maximizes contact between the sclerosant and the vein wall. This contact causes endothelial injury, inflammation, and thrombosis, leading to vein fibrosis and permanent closure. The microfoam formulation allows for lower doses and improved efficacy compared to liquid sclerosants.
Approved indications
- Varicose veins of the great saphenous vein, accessory saphenous vein, and visible varicosities
Common side effects
- Injection site pain or bruising
- Thrombophlebitis
- Headache
- Dizziness
- Dyspnea
- Chest pain
Key clinical trials
- Varithena Versus Endothermal Ablation of the Great Saphenous Vein (VERITAS) (PHASE4)
- Efficacy of the SALFOAM 3% Method Compared to the Conventional Polidocanol Foam Method (Tessari Method) for Treating Lower Limb Varicose Veins (NA)
- Embolization Strategies for Pelvic Venous Disorders: Foam + Glue vs Foam + Coils (NA)
- RCT Comparing EVLA Versus Polidocanol Foam in the Treatment of SSV Insufficiency (NA)
- Effect of VarIthena on Wound Healing in Venous Leg Ulcers (VLU)
- Efficacy and Safety of Polidocanol Foam 3% in the Treatment of II Degree Hemorrhoidal Disease (PHASE2)
- An Open-label, Single-dose Pilot Study to Evaluate Varisolve® (Polidocanol Endovenous Microfoam (PEM)) 0.125% [0.2%] for Varicose Veins (PHASE2)
- Safety Study of Varisolve® Procedure for Treatment of Varicose Veins in Patients With Right-to-left Cardiac Shunt (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Varithena® CI brief — competitive landscape report
- Varithena® updates RSS · CI watch RSS
- Boston Scientific Corporation portfolio CI